Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial

Pascal Turlure, MD, Nathalie Cambier, MD, Murielle Roussel, Sylvia Bellucci, MD, PhD, Jean-Marc Zini, MD, PhD, Jean-Didier Rain, MD, Philippe Rousselot, MD, PhD, William Vainchenker, MD, PhD, Lina Abdelkader, Kamel Ghomari, Jean-Luc Dutel, Yasmine Chait, Sylvie Chevret, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, Jean-Jacques Kiladjian, MD, PhD

Blood (2011) 118 (21): 280.

https://doi.org/10.1182/blood.V118.21.280.280

Published: 2011

Journal Articles

Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi).

Jean-Jacques Kiladjian, Sylvie Chevret, Christine Dosquet, Pierre Fenaux, Christine Chomienne, Jean-Didier Rain

Blood (2008) 112 (11): 1746.

https://doi.org/10.1182/blood.V112.11.1746.1746

Published: 2008

Journal Articles

Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α 5 chain and Lu/BCAM

Marie-Paule Wautier, Wassim El Nemer, Pierre Gane, Jean-Didier Rain, Jean-Pierre Cartron, Yves Colin, Caroline Le Van Kim, Jean-Luc Wautier

Blood (2007) 110 (3): 894–901.

https://doi.org/10.1182/blood-2006-10-048298

Published: 2007

Includes: Supplemental data

Journal Articles

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Jehan Dupuis, MD, Emmanuel Itti, MD,PhD, Alain Rahmouni, MD,PhD, Jean-Didier Rain, MD,PhD, Christian Gisselbrecht, MD,PhD, Karim Belhadj, MD, Taoufik El Gnaoui, MD, Isabelle Gaillard, MD, Chieh Lin, MD, Nicolas Mounier, MD,PhD, Philippe Gaulard, MD,PhD, Michel Meignan, MD,PhD, Felix Reyes, MD,PhD, Corinne Haioun, MD

Blood (2006) 108 (11): 2735.

https://doi.org/10.1182/blood.V108.11.2735.2735

Published: 2006

Journal Articles

Peg IFNα-2a in Polycythemia Vera (PV). Results of a Phase 2 Study by the French “PV-NORD” Group.

Jean-Jacques Kiladjian, MD, Bruno Cassinat, MD, Pascal Turlure, MD, Nathalie Cambier, MD, Sylvia Bellucci, MD,PhD, Murielle Roussel, MD, Marie-José Grange, MD, Bernard Grandchamp, MD,PhD, Jean-Didier Rain, MD,PhD, Christine Chomienne, MD,PhD, Pierre Fenaux, MD,PhD

Blood (2006) 108 (11): 670.

https://doi.org/10.1182/blood.V108.11.670.670

Published: 2006

Journal Articles

High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a

Blood (2006) 108 (6): 2037–2040.

https://doi.org/10.1182/blood-2006-03-009860

Published: 2006

Journal Articles

Monoclonal immunoglobulin with antitransferrin activity: a rare cause of hypersideremia with increased transferrin saturation

Marie-Alexandra Alyanakian, Youri Taes, Mimouna Bensaïd, Berta Segovia, Pierre Aucouturier, Jean-Didier Rain, Joris Delanghe, Bruno Varet, Carole Beaumont

Blood (2006) 109 (1): 359–361.

https://doi.org/10.1182/blood-2006-05-023762

Published: 2006

Includes: Supplemental data

Journal Articles

High Response Rate to Epoetin Beta in Elderly Patients with Myelodysplasia (MDS): Results of a Prospective Study.

Pascal Chaibi, MD, Isabelle Gouin, MD, Sylvie Berigaud, MD, Virginie Siguret, MD, Eric Pautas, MD, Marie Helene Schlageter, MD, Jean Didier Rain, Emmanuel Raffoux

Blood (2005) 106 (11): 2538.

https://doi.org/10.1182/blood.V106.11.2538.2538

Published: 2005

Journal Articles

PVN1: A Phase 2 Study of Pegylated Interferon-α2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety.

Jean-Jacques Kiladjian, MD, Bruno Cassinat, MD, Pascal Turlure, MD, Sylvia Bellucci, MD, Nathalie Cambier, MD, Murielle Roussel, MD, Marie-José Grange, MD, Jean-Didier Rain, MD, Christine Chomienne, MD, Pierre Fenaux, MD

Blood (2005) 106 (11): 4940.

https://doi.org/10.1182/blood.V106.11.4940.4940

Published: 2005

Journal Articles

[ 18 F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

Corinne Haioun, Emmanuel Itti, Alain Rahmouni, Pauline Brice, Jean-Didier Rain, Karim Belhadj, Philippe Gaulard, Laurent Garderet, Eric Lepage, Felix Reyes, Michel Meignan

Blood (2005) 106 (4): 1376–1381.

https://doi.org/10.1182/blood-2005-01-0272

Published: 2005

Journal Articles

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells

Jérôme Larghero, Nathalie Gervais, Bruno Cassinat, Jean-Didier Rain, Marie-Hélène Schlageter, Rose Ann Padua, Christine Chomienne, Philippe Rousselot

Blood (2005) 105 (9): 3743–3745.

https://doi.org/10.1182/blood-2004-07-2949

Published: 2005

Journal Articles

Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia

Bruno Cassinat, Philippe Guardiola, Sylvie Chevret, Marie-Hélène Schlageter, Marie-Elisabeth Toubert, Jean-Didier Rain, Eliane Gluckman

Blood (2000) 96 (3): 859–863.

https://doi.org/10.1182/blood.V96.3.859

Published: 2000

Journal Articles

Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years

Yves Najean, Jean-Didier Rain

Blood (1997) 90 (9): 3370–3377.

https://doi.org/10.1182/blood.V90.9.3370

Published: 1997

Journal Articles

Treatment of Polycythemia Vera: Use of 32 P Alone or in Combination With Maintenance Therapy Using Hydroxyurea in 461 Patients Greater Than 65 Years of Age

Yves Najean, Jean-Didier Rain

Blood (1997) 89 (7): 2319–2327.

https://doi.org/10.1182/blood.V89.7.2319

Published: 1997

NARROW

Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial

Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi).

Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α 5 chain and Lu/BCAM

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Peg IFNα-2a in Polycythemia Vera (PV). Results of a Phase 2 Study by the French “PV-NORD” Group.

High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a

Monoclonal immunoglobulin with antitransferrin activity: a rare cause of hypersideremia with increased transferrin saturation

High Response Rate to Epoetin Beta in Elderly Patients with Myelodysplasia (MDS): Results of a Prospective Study.

PVN1: A Phase 2 Study of Pegylated Interferon-α2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety.

[ 18 F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells

Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia

Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years

Treatment of Polycythemia Vera: Use of 32 P Alone or in Combination With Maintenance Therapy Using Hydroxyurea in 461 Patients Greater Than 65 Years of Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only